---

---

publishing date : 2021 - 12 - 10    tags : Cancer   

save search

---

Jaguar Health Announces the Presentation of Findings from the Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients at San Antonio Breast Cancer Symposium (SABCS 2021)
Published: 2021-12-10 (Crawled : 16:20) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M |

Health Technology

| -88.06% | O: 5.22% H: 0.0% C: 0.0%
health phase 2 symposium sabcs presentation diarrhea therapy cancer breast cancer initiated crofelemer

---

Artificial Intelligence Being Used to Accurately Predict Synergistic Cancer Drug Combinations
Published: 2021-12-10 (Crawled : 19:00) - prnewswire.com
BMY | $48.93 1.3% 0.0% 10M |

Health Technology

| Email alert Add to watchlist
MRTX | $58.7 -0.17% 0.34% 0 |

Health Technology

| Email alert Add to watchlist
AMGN | $269.03 2.39% 2.33% 3.4M |

Health Technology

| Email alert Add to watchlist
ONCY | $1.045 -3.24% -3.35% 180K |

Health Technology

| Email alert Add to watchlist
MRK | News | $125.78 0.44% 0.0% 8.4M |

Health Technology

| Email alert Add to watchlist
artificial intelligence drug cancer drug cancer

---

Trodelvy® Demonstrates Clinical Benefit for Black Patients Consistent with Full Metastatic Triple-Negative Breast Cancer Population in ASCENT Study
Published: 2021-12-10 (Crawled : 15:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M |

Health Technology

| -5.04% | O: -0.17% H: 0.0% C: 0.0%
trodelvy cancer negative breast cancer

---

Hologic Presents Breast Cancer Index™ Data at SABCS 2021 Showing Net Benefit Predictive Value for Endocrine Therapy Continuation
Published: 2021-12-10 (Crawled : 14:30) - biospace.com/
HOLX | $75.37 0.36% 0.36% 1.3M |

Health Technology

| -1.11% | O: -1.42% H: 0.0% C: 0.0%
sabcs therapy endocrine cancer breast cancer

---

Intensity Therapeutics Reports Promising Early Efficacy Results Using INT230-6 as a Monotherapy or in Combination with Pembrolizumab in Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer Symposium®
Published: 2021-12-10 (Crawled : 14:30) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M |

Health Technology

| -14.96% | O: 0.0% H: 0.0% C: 0.0%
int230 symposium therapeutics therapy results cancer breast cancer metastatic breast cancer

---

Encouraging Updated Data from Phase 2 MARIO-3 TNBC Trial Presented at 2021 San Antonio Breast Cancer Symposium
Published: 2021-12-10 (Crawled : 14:30) - biospace.com/
INFI | $0.016 12.5% 1.1M |

Health Technology

| -99.31% | O: 1.29% H: 0.0% C: 0.0%
phase 2 symposium trial cancer breast cancer

---

Cardiff Oncology Announces Upcoming Presentation on Lead KRAS-mutated Metastatic Colorectal Cancer Program at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
Published: 2021-12-10 (Crawled : 14:30) - biospace.com/
CRDF | $4.34 -0.69% -0.69% 610K |

Health Services

| -24.74% | O: 1.9% H: 0.0% C: 0.0%
symposium gastrointestinal presentation test cancer colorectal cancer

---

Big Trend Occurring in Triple-Negative Breast Cancer Treatment Is The Shift Towards Combination Therapy
Published: 2021-12-10 (Crawled : 14:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K |

Health Technology

| -38.55% | O: -6.7% H: 0.0% C: 0.0%
NKTR | News | $1.265 -4.17% -4.35% 4.7M |

Health Technology

| -90.21% | O: -0.47% H: 0.0% C: 0.0%
IMGN | $31.23 0.03% 49M |

Health Technology

| 332.39% | O: -4.78% H: 0.0% C: 0.0%
HOLX | $75.37 0.36% 0.36% 1.3M |

Health Technology

| -1.11% | O: -1.42% H: 0.0% C: 0.0%
BCTX | $2.19 -5.6% -5.94% 140K |

Professional, Scientific, and T...

| -70.72% | O: -13.0% H: 0.0% C: 0.0%
treatment therapy cancer negative breast cancer

---

Relay Therapeutics Announces Preclinical Data that Support Clinical Development of RLY-2608 as Both a Single Agent and in CombinationRLY-2608 combines with standard of care therapies to drive regressions in ER+/HER2- breast cancer models
Published: 2021-12-10 (Crawled : 13:30) - biospace.com/
RLAY | $5.96 -2.46% -2.52% 2.4M |

Health Technology

| -80.75% | O: -5.65% H: 0.0% C: 0.0%
rly-2608 therapeutics preclinical cancer breast cancer pre-clinical her2- her2

---

Candel Therapeutics and Partnership for Accelerating Cancer Therapies (PACT) to Collaborate on Lung Cancer Trial for CAN-2409
Published: 2021-12-10 (Crawled : 13:30) - globenewswire.com
CADL | $5.17 -5.31% -5.61% 520K |

| -42.68% | O: -2.66% H: 3.08% C: 0.46%
can-2409 partnership trial therapeutics lung cancer cancer therapy

---

BeyondSpring Pharmaceuticals Announces Analysis of New Data on the Plinabulin/Pegfilgrastim Combination in Breast Cancer at the 2021 San Antonio Breast Cancer Symposium
Published: 2021-12-10 (Crawled : 13:30) - globenewswire.com
BYSI | $1.8 -2.21% 80K |

Health Technology

| -59.96% | O: -5.03% H: 0.0% C: 0.0%
symposium cancer plinabulin breast cancer

---

Merus Presents Updated Analysis of Zenocutuzumab, Trastuzumab, and Vinorelbine in Patients with HER2+ Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium
Published: 2021-12-10 (Crawled : 13:30) - globenewswire.com
MRUS | $39.83 -1.58% -1.61% 800K |

Health Technology

| 49.55% | O: 2.85% H: 0.0% C: 0.0%
symposium cancer her2+ breast cancer her2- her2 metastatic breast cancer

---

Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer
Published: 2021-12-10 (Crawled : 13:30) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M |

Health Technology

| -49.53% | O: -0.52% H: 0.0% C: 0.0%
ARVN | $34.78 1.43% 1.41% 940K |

Health Technology

| -52.65% | O: -2.1% H: 0.0% C: 0.0%
arv-471 protac cancer breast cancer her2- her2

---

Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i
Published: 2021-12-10 (Crawled : 13:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K |

Health Technology

| 15.29% | O: -1.81% H: 0.0% C: -0.31%
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| 16.66% | O: -0.49% H: 0.0% C: 0.0%
piqray novartis media cancer breast cancer her2- her2 metastatic breast cancer

---

Oncolytics Biotech® Presents Positive Interim Safety Update from Phase 2 Triple-Negative Breast Cancer Trial at the 2021 San Antonio Breast Cancer Symposium
Published: 2021-12-10 (Crawled : 12:30) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K |

Health Technology

| -38.55% | O: -6.7% H: 0.0% C: 0.0%
biotech phase 2 symposium trial positive cancer negative iot breast cancer

---

GENE Presents Study Involving 200,000 Participants at 2021 San Antonio Breast Cancer Symposium
Published: 2021-12-10 (Crawled : 12:30) - globenewswire.com
GENE 1 d | $2.27 -6.97% -7.49% 64K |

Health Technology

| -2.52% | O: -12.18% H: 0.0% C: 0.0%
symposium cancer breast cancer

---

NeoGenomics to Leverage Thermo Fisher Scientific’s Ion Torrent Genexus System in Upcoming Phase 1 Study for Myeloid Cancer
Published: 2021-12-10 (Crawled : 12:30) - biospace.com/
NEO | $13.54 -1.67% -1.7% 770K |

Health Services

| -59.85% | O: -0.61% H: 0.0% C: 0.0%
genomics genomic phase 1 cancer phase 2

---

Gainers vs Losers

67%

33%

Top 10 Gainers

---

Your saved searches

---